TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11042828

Group type: EXPERIMENTAL
Intervention: hCG injection followed by oocyte retrieval at 34 hours (group A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: hCG injection followed by oocyte retrieval at 38 hours (group B)
Number of subjects: 170
Study: 8957645

Group type: EXPERIMENTAL
Intervention: Benzoic acid (2 concentrations)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trans-cinnamic acid (2 concentrations)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Methyl nicotinate (2 concentrations)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 200

Group type: COMPARATOR
Intervention: General observation
Number of subjects: 200
Study: 1416127

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (10 micrograms)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (10 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 micrograms)
Number of subjects: 65
Study: 3912695

Group type: EXPERIMENTAL
Intervention: Crossover regime: adriamycin (40 mg/m2 day 1), cisplatin (100 mg/m2 day 2), vincristine (1.4 mg/m2 day 28), cyclophosphamide (1,500 mg/m2 day 25), methotrexate (1,000 mg/m2 day 56) (2 cycles)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Adriamycin (40 mg/m2) and cisplatin (50 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Crossover regime for patients with highly differentiated tumors
Number of subjects: 150

Group type: COMPARATOR
Intervention: Other regimens for patients with less differentiated tumors
Number of subjects: 150
Study: 31117967

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin regimen (30-40 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Triweekly cisplatin regimen (80-100 mg/m2 on days 1, 22, and 43)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin regimen
Number of subjects: 322

Group type: COMPARATOR
Intervention: Triweekly cisplatin regimen
Number of subjects: 322
Study: 28544397

Group type: EXPERIMENTAL
Intervention: High-velocity microdroplet device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-velocity microdroplet device and Dental floss
Number of subjects: 60
Study: 26041583

Group type: EXPERIMENTAL
Intervention: Nordic nutrition recommendations (NNR diet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Palaeolithic diet (PD)
Number of subjects: 12
Study: 24861492

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 100
Study: 22648722

Group type: COMPARATOR
Intervention: B vitamins (0.56 mg 5-methyl-tetrahydrofolate, 3 mg B-6, 0.02 mg B-12)
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA and DHA 600 mg in a 2:1 ratio)
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study: 20200382

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Dopamine (in cardiogenic shock)
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Norepinephrine (in cardiogenic shock)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Dopamine (in septic shock)
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Norepinephrine (in septic shock)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Dopamine (in hypovolemic shock)
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Norepinephrine (in hypovolemic shock)
Number of subjects: 1679
Study: 18056580

Group type: EXPERIMENTAL
Intervention: PD‐PCP in 'off' condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: PD‐NoP in 'off' condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy control subjects in 'off' condition
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PD‐PCP in 'on' condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: PD‐NoP in 'on' condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy control subjects in 'on' condition
Number of subjects: 27
Study: 16142802

Group type: EXPERIMENTAL
Intervention: abciximab during PTCA (group 1, 70 patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: conventional treatment without GP IIb/IIIa inhibitor (group 2, 70 patients)
Number of subjects: 140
Study: 12141722

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10447220

Group type: EXPERIMENTAL
Intervention: Lifibrol therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Simvastatin therapy
Number of subjects: 4
Study: 7823387

Group type: EXPERIMENTAL
Intervention: Inadequate allocation concealment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Unclear allocation concealment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Exclusions after randomization
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Non-double-blind trials
Number of subjects: 250
Study: 2276311

Group type: EXPERIMENTAL
Intervention: Timolol-treated eyes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo-treated eyes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 31631472

Group type: EXPERIMENTAL
Intervention: WhatsApp (WA) group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Electronic mail (eM) group
Number of subjects: 74
Study: 30888751

Group type: EXPERIMENTAL
Intervention: LAM plus Adefovir (ADV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 30
Study: 28126349

Group type: EXPERIMENTAL
Intervention: Full-spectrum endoscopy (FUSE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional forward-viewing colonoscopy (FVC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Targeted tissue acquisition
Number of subjects: 52
Study: 25772684

Group type: EXPERIMENTAL
Intervention: Microbial sealant (InteguSeal© Kimberly‐Clark)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No microbial sealant (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 100
Study: 23085970

Group type: EXPERIMENTAL
Intervention: Velocity-based training (VEL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intensity-based training (INT)
Number of subjects: 32
Study: 21402601

Group type: EXPERIMENTAL
Intervention: Extended callback counselling (4 to 6 calls delivered 1-3 months after quitting)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Usual care (4 calls in the first month after quitting)
Number of subjects: 698
Study: 17602098

Group type: EXPERIMENTAL
Intervention: 3-year television/radio campaign aimed at adolescent smoking cessation
Number of subjects: 2030

Group type: COMPARATOR
Intervention: No media campaign (comparison group)
Number of subjects: 2030
Study: 17207299

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg 6 hourly for 7 days plus continuous wound infusion of ropivacaine 0.75% for 30 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules identical to those of gabapentin for 7 days and continuous wound infusion of normal saline for 30 h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gabapentin and ropivacaine treatment
Number of subjects: 60
Study: 15494620

Group type: EXPERIMENTAL
Intervention: Clinic-based home assessment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 200
Study: 12575605

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) therapy for relieving blood stasis, invigorating Spleen and soothing Liver, administered for 5-6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 9127390

Group type: EXPERIMENTAL
Intervention: VVI pacing at a rate of 60 beats/min
Number of subjects: 20
Study: 8161954

Group type: EXPERIMENTAL
Intervention: Bolus of water ingested 2 hours before induction of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no water bolus)
Number of subjects: 0
Study: 2894911

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg X 2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg X 2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: propranolol 80 mg X 2
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo X 2
Number of subjects: 32
Study: 31858696

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist intervention for 6 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 55
Study: 31096654

Group type: EXPERIMENTAL
Intervention: Selective aluminum CFI (60 HB Brinell hardness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polypropylene CFI (58° Shore D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethylene vinyl acetate CFI (EVA) (52° Shore A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard EVA (25° Shore A)
Number of subjects: 0
Study: 28056933

Group type: EXPERIMENTAL
Intervention: MOVEdiabetes programme (intervention)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 154
Study: 25592254

Group type: EXPERIMENTAL
Intervention: amodiaquine‐artesunate (AQ‐AS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin‐piperaquine (DHA‐PQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: artemether‐lumefantrine (AL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mefloquine‐artesunate (MQAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments (AQ‐AS, DHA‐PQ, AL, MQAS)
Number of subjects: 0
Study: 24018227

Group type: EXPERIMENTAL
Intervention: Mobile eye-tracking procedure
Number of subjects: 0
Study: 21533301

Group type: EXPERIMENTAL
Intervention: OTC petroleum-based skin protectant moisturizer (OTC-Pet, Aquaphor Healing Ointment®)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®)
Number of subjects: 39

Group type: COMPARATOR
Intervention: BRC-Gly, BRC-Cer
Number of subjects: 39
Study: 18096281

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention delivered by trained nurses; duration between 5 and 65 minutes.
Number of subjects: 195
Study: 17062450

Group type: EXPERIMENTAL
Intervention: Spirituality group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cognitive Support group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Emotional Support group
Number of subjects: 122
Study: 14633817

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 11147601

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 6467

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 6467
Study: 8602315

Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bacteriostatic saline
Number of subjects: 52
Study: 10146979

Group type: EXPERIMENTAL
Intervention: Clentiazem (calcium channel blocker)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Symptom checklist
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open-ended question method
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 88
Study: 2934438

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon injected three times a week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (placebo) injected three times a week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Topical placebo ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Topical betamethasone ointment
Number of subjects: 12
Study: 30052277

Group type: EXPERIMENTAL
Intervention: Dark triad personality (DTP) traits, specifically Machiavellianism
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mediators (organizational commitment and organizational justice)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Psychological contract breach
Number of subjects: 168
Study: 28256397

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Static-dynamic stretching protocol
Number of subjects: 17
Study: 26645922

Group type: EXPERIMENTAL
Intervention: Elastic bandage wrap applied to leg for 8 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unwrapped leg (control)
Number of subjects: 24
Study: 23621432

Group type: EXPERIMENTAL
Intervention: CO2 cholangiogram
Number of subjects: 36

Group type: COMPARATOR
Intervention: Iodine contrast (control group)
Number of subjects: 36
Study: 22030947

Group type: COMPARATOR
Intervention: 250 mg caffeine (C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg geranamine (G 50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 mg geranamine (G 75 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine + 50 mg geranamine (C + G 50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine + 75 mg geranamine (C + G 75 mg)
Number of subjects: 10
Study: 18465339

Group type: EXPERIMENTAL
Intervention: Ovarian ablation (OA)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Nine courses of three-weekly cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 1628
Study: 16132165

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600
Study: 15557380

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 145
Study: 11756615

Group type: EXPERIMENTAL
Intervention: 4 g acetaminophen daily (n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matched placebo (n = 22)
Number of subjects: 42
Study: 9314634

Group type: EXPERIMENTAL
Intervention: Diabetes team intervention (diabetes nurse educator and endocrinologist)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Diabetes team intervention
Number of subjects: 179
Study: 8338289

Group type: EXPERIMENTAL
Intervention: Short‐CY (pulse cyclophosphamide 0.5 to 1.0 g/m2 body surface area monthly for 7 doses)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Long‐CY (pulse cyclophosphamide 0.5 to 1.0 g/m2 body surface area monthly for 15 or more doses)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Short‐CY
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Short‐CY vs Long‐CY (age > 25 years)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (methylprednisolone 1.0 g/m2 monthly for 9 doses)
Number of subjects: 39
Study: 3551577

Group type: EXPERIMENTAL
Intervention: Copovithane schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Copovithane schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months
Number of subjects: 30
Study: 29557290

Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F)
Number of subjects: 12

Group type: COMPARATOR
Intervention: e-guidance (EC)
Number of subjects: 12
Study: 26803086

Group type: EXPERIMENTAL
Intervention: Pharmacist-led motivational interviewing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard discharge care (Control)
Number of subjects: 30
Study: 24805184

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 0

Group type: COMPARATOR
Intervention: boosted lopinavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART (general)
Number of subjects: 0
Study: 23111127

Group type: EXPERIMENTAL
Intervention: Website intervention (n = 6055)
Number of subjects: 12287

Group type: COMPARATOR
Intervention: No-intervention control group (n = 6232)
Number of subjects: 12287
Study: 20554978

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 2292
Study: 18515521

Group type: EXPERIMENTAL
Intervention: Sinecatechins ointment 15%
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Sinecatechins ointment 10%
Number of subjects: 502

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 502
Study: 16548420

Group type: EXPERIMENTAL
Intervention: Chicken Essence (CE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11728498

Group type: EXPERIMENTAL
Intervention: Non-closure of visceral peritoneum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Closure of visceral peritoneum
Number of subjects: 100
Study: 9154289

Group type: EXPERIMENTAL
Intervention: Latanoprost eye drops
Number of subjects: 100
Study: 7893988

Group type: EXPERIMENTAL
Intervention: poly(I)-poly(C12U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 3312658

Group type: EXPERIMENTAL
Intervention: Clotrimazole troches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 60
Study: 29743534

Group type: EXPERIMENTAL
Intervention: Community detection algorithms (modularity maximisation, graph partitioning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 26719035

Group type: EXPERIMENTAL
Intervention: Regular concurrent exercise training for 30 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 23813320

Group type: EXPERIMENTAL
Intervention: Personal contact
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Interactive technology
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Self‐directed
Number of subjects: 1032
Study: 21740829

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1159
Study: 19460078

Group type: EXPERIMENTAL
Intervention: Conventional right atrial appendage pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low atrial septal pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of different pacing sites and AF suppression pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16997840

Group type: EXPERIMENTAL
Intervention: LMA CTrach (CT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 104
Study: 15568249

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy combined with supragingival and subgingival scaling therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supragingival and subgingival scaling therapy
Number of subjects: 0
Study: 11157369

Group type: EXPERIMENTAL
Intervention: High dialysate calcium concentration (HDCa; 3.5 mEq/L)
Number of subjects: 28
Study: 9401410

Group type: EXPERIMENTAL
Intervention: IgAN < 45
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IgAN > 45
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IgAN < 45 and IgAN > 45
Number of subjects: 38
Study: 8492688

Group type: EXPERIMENTAL
Intervention: High volume resistance exercise (HVRE)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low volume resistance exercise (LVRE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (C) [no exercise]
Number of subjects: 7
Study: 2851958

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid suture (interrupted)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Polyglyconate suture (continuous)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Polypropylene suture (continuous)
Number of subjects: 195
Study: 29547978

Group type: EXPERIMENTAL
Intervention: Stimulant medication ON
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stimulant medication OFF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 28383533

Group type: EXPERIMENTAL
Intervention: One capsule of daily iron supplement (34 mg of ferrous sulfate)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Two capsules of daily iron supplement (34 mg of ferrous sulfate)
Number of subjects: 324
Study: 26488676

Group type: EXPERIMENTAL
Intervention: Low-dose mirtazapine
Number of subjects: 0
Study: 24200934

Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (8 g Chlorella/day/person; equivalent to 22.9 mg lutein/day/person)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21362764

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18682188

Group type: EXPERIMENTAL
Intervention: 3‐S saphenectomy with distal sclerosis
Number of subjects: 105

Group type: COMPARATOR
Intervention: 3‐S saphenectomy
Number of subjects: 105
Study: 21324452

Group type: EXPERIMENTAL
Intervention: Individualized aerobic exercise training for 16 weeks
Number of subjects: 8
Study: 16021664

Group type: EXPERIMENTAL
Intervention: Late-onset recurrent depression
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Late-onset single-episode depression
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Early-onset recurrent depression
Number of subjects: 181
Study: 12422941

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0